Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

lation phase, expected during the second quarter of 2014, with final study results expected in the second half of 2014. Future development plans for BL-8040 include entering into additional hematological indications, including the commencement of clinical studies in stem cell mobilization and chronic myeloid leukemia during the first half of 2014."

Dr. Gautam Borthakur, the principal investigator from the world-renowned MD Anderson Cancer Center in Houston, stated, "AML is a disease with a clear need for new and more effective treatments. Current options are rather limited, and the five-year survival rate is low compared to many other blood cancers. This is particularly true with respect to patients with relapsed or refractory diseases. The initial results of the BL-8040 Phase 2 trial show a remarkable apoptotic effect of the drug on AML cancer cells, and the drug is exceptional in its ability to induce both mobilization of cancer cells from the bone marrow, as well as a concomitant cell death effect. I therefore have high hopes that this drug will become an important addition to the limited drug arsenal for AML treatment."

About BL-8040
BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia and other hematological indications. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in retention of cancer cells in the bone marrow, tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a Phase 1/2, open-label, dose escalation, safety and efficacy clinical trial in 18 multiple myeloma patients, BL-8040 demonstrated an excellent safety profile at all doses tested and was high
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Financial Officer of Neurocrine Biosciences, will be presenting at ... York City . The live presentation ... (8:25am PT).  The presentation will be webcast and may ... .   Listeners are encouraged to visit ...
(Date:9/2/2015)... Demers Ambulances is proud to announce it has signed Emergency ... states of Mississippi , Alabama ... "This will enable Demers to effectively meet the needs ... for Demers Ambulances. "Emergency Equipment Professionals has three service centers ... Alabama , giving them a strategic advantage. Local service ...
(Date:9/2/2015)... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company,s Board of Directors has engaged Morgan Stanley ... alternatives to maximize shareholder value. Potential ... review process may include a possible sale of the ...
Breaking Medicine Technology:Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2Unilife Announces Review of Strategic Alternatives 2
... 17, 2007 - Inovio Biomedical,Corporation (AMEX:INO), focused ... and infectious diseases and a novel,alternative to ... partners of the company will present new ... of plasmid-based immunotherapies using,Inovio's electroporation delivery technology ...
... -- DURECT,Corporation announced today that Voyager Pharmaceutical ... its truncated Phase 3,clinical trial for Memryte, ... disease. Voyager has informed its,shareholders that they ... no positive effect among men. DURECT has ...
Cached Medicine Technology:Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials 2Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials 3Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials 4DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp 2
(Date:9/2/2015)... ... ... Good health and a good cause paired up at The Barclays this ... $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. After ... Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to add more ...
(Date:9/2/2015)... ... 02, 2015 , ... The Hydration Room, Orange County’s first ... second location this week at 31542 S. Coast Hwy, Suite #4, Laguna Beach, ... for patients to relax while receiving safe and effective therapies. Also offering complimentary ...
(Date:9/2/2015)... WI (PRWEB) , ... September 02, 2015 , ... ... Cypress Benefit Administrators is taking action after seeing a significant increase ... TPA’s Argus Claim Review division has found many cases of OON ASCs encouraging ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Amada Senior Care, ... office in Kansas – its Johnson County location. Amada franchise partners Mike ... has a registered nurse background and spent over 20 years in medical device sales ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... Wash. , Feb. 4 The Carol Milgard Breast ... and Drug Administration (FDA) for adhering to the most rigorous quality ... (MQSA).  Receiving the "All Items in Compliance" rating from the FDA ... not received this high quality standard.   , John Peixotto ...
... PALM BEACH, Fla. , Feb. 4 The American ... suffer from some type of cardiovascular disease. Many of those people ... event like the Super Bowl or World Cup where the tension ... rates from heart attacks in 2002 and 2001, doctors in ...
... cancer is the second leading cause of cancer-related deaths in ... of screening for this disease, rates of screening for colorectal ... cancer, particularly breast and cervical. Although the screening rates in ... from 20-30 percent in 1997 to nearly 55 percent in ...
... for athletes to cheat, researchers say , THURSDAY, Feb. 4 ... scientists are warning of a new breed of performance-enhancing agents ... to detect. , , Some researchers are already ... how they can modify genes to boost endurance or muscle ...
... , GAINESVILLE, Fla. , Feb. 4 ... announce today that they have jointly selected Sg2 , a healthcare ... children,s hospital. The assessment began in January with findings projected to be ... at Sg2 will handle this very important assessment, delivering the ...
... , , , ... /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), ... materials for,use in pharmaceutical, nutraceutical and food production, today announced,preliminary ... Huifeng Bio-Pharmaceutical Technology anticipates revenues between $13,million ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Panel calls for reducing colorectal cancer deaths by striking down barriers to screening 2Health News:'Gene Doping' May Be Next Wave of Sports Tampering 2Health News:'Gene Doping' May Be Next Wave of Sports Tampering 3Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: